Abstract
Allergan and Editas Medicine have established an ophthalmic-disease-related R&D alliance. Allergan will pay $90 million up front to access up to five early-stage CRISPR genome-editing programs at Editas. Included is Editas’s lead program for Leber congenital amaurosis, a rare, inherited retinal degenerative disease. Allergan will be responsible for developing and commercializing any resulting products. Editas could codevelop up to two.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have